How Peptides Block HIV Entry: Fusion Inhibitors
HIV Peptides
< 2 ng/mL IC50 for T-20
The peptide T-20 (enfuvirtide) blocked HIV cell fusion at concentrations below 2 nanograms per milliliter in vitro, demonstrating that a 36-amino-acid peptide can match the potency of small-molecule antivirals.
Kilby et al., Nature Medicine, 1998
Kilby et al., Nature Medicine, 1998
View as imageHIV cannot infect a cell without fusing its membrane with the host cell membrane. That fusion event depends on a single viral protein, gp41, folding into a specific structure called the six-helix bundle (6HB). Block that fold, and the virus cannot enter. Wild et al. (1994) demonstrated this principle by synthesizing DP-178, a 36-amino-acid peptide corresponding to the C-terminal heptad repeat (HR2) region of gp41, which inhibited HIV-1 infection with IC50 values in the nanomolar range.[1] That peptide became enfuvirtide (Fuzeon), the first FDA-approved fusion inhibitor. For a broader look at HIV peptide research, see peptide-based HIV vaccines: the ongoing search for immunization. For the development history of enfuvirtide, see the T-20 peptide story.
Key Takeaways
- Wild et al. (1994) identified DP-178 (later enfuvirtide), a 36-aa peptide from the gp41 HR2 region that inhibited HIV fusion in vitro at nanomolar concentrations[1]
- Kilby et al. (1998) showed T-20 achieved 1.96 log10 reductions in viral load in HIV-infected patients at 100 mg twice daily in the first human trial[2]
- The mechanism is specific: peptides bind the gp41 HR1 trimer groove, physically preventing HR2 from packing against it to form the six-helix bundle[3]
- Resistance develops through mutations at position 36-45 of HR1, particularly at residue 38 (Cooper et al., 2004)[3]
- Saha et al. (2026) created nanobody-fusion inhibitor conjugates with 100-fold greater potency than enfuvirtide alone[4]
- The fusion inhibitor mechanism has been extended to SARS-CoV-2, RSV, Ebola, and other enveloped viruses with class I fusion proteins (Gonepudi et al., 2025)[5]
How HIV Enters a Cell
HIV entry is a multi-step process that creates several intervention points for peptide-based drugs.
Step 1: Attachment. The viral surface protein gp120 binds to CD4 on the target cell. This triggers a conformational change in gp120 that exposes the binding site for a co-receptor (CCR5 or CXCR4).
Step 2: Co-receptor binding. gp120 binds the co-receptor, triggering a second conformational change that activates the transmembrane protein gp41.
Step 3: Fusion peptide insertion. gp41 extends its hydrophobic fusion peptide into the target cell membrane, anchoring the virus to the host cell. Serrano et al. (2017) investigated the structure-function relationships of this fusion peptide, finding that its conserved FLGFLG repeat sequence is essential for membrane insertion and cannot be replaced by other hydrophobic sequences.[6]
Step 4: Six-helix bundle formation. Three HR1 domains fold into a trimeric coiled-coil core. Three HR2 domains then pack into the grooves of the HR1 trimer in an antiparallel orientation, forming the 6HB. This brings the viral and cell membranes into close apposition.
Step 5: Membrane fusion. The energy released by 6HB formation pulls the two membranes together, creating a fusion pore through which the viral contents enter the cell.
Peptide fusion inhibitors act between steps 3 and 4. After the fusion peptide has inserted into the host membrane but before the 6HB has formed, there is a transient window where the HR1 trimer is exposed. Peptides that bind HR1 during this window prevent HR2 from completing the 6HB, trapping the virus in a non-functional intermediate state.
The Molecular Mechanism
HR2-Mimetic Peptides
Enfuvirtide (T-20/DP-178) is a synthetic 36-amino-acid peptide that mimics the HR2 region of gp41 (residues 643-678). It acts as a competitive inhibitor: by binding to the HR1 trimer groove, it physically occupies the space where native HR2 would pack, preventing 6HB closure.
The binding is highly specific. Enfuvirtide's alpha-helical structure complements the hydrophobic grooves on the HR1 trimer surface. The interaction involves leucine zipper-like contacts between hydrophobic residues on both the peptide and the HR1 target. Cooper et al. (2004) described enfuvirtide's extracellular mechanism as both its strength and its limitation: because it acts outside the cell, it avoids intracellular drug-drug interactions but requires parenteral administration since oral delivery would result in proteolytic degradation.[3]
Why This Works Against Resistant Strains
Because enfuvirtide acts at the entry step rather than on intracellular enzymes (reverse transcriptase, protease, integrase), it is active against HIV strains resistant to all other drug classes. A virus that has accumulated resistance mutations in its reverse transcriptase or protease still uses the same gp41-mediated fusion mechanism to enter cells. This made enfuvirtide a critical salvage therapy option for heavily treatment-experienced patients when it was approved in 2003.
From Discovery to Clinical Proof
Wild et al. (1994) synthesized DP-178 based on a predictive analysis of gp41's alpha-helical domains. The peptide inhibited HIV-1 cell-cell fusion and free virus infection with IC50 values of approximately 1 ng/mL in vitro.[1]
Kilby et al. (1998) conducted the first human study, administering T-20 (DP-178 renamed) intravenously to 16 HIV-infected adults for 14 days. The results were striking: dose-dependent viral load reductions occurred across all four dose groups (3, 10, 30, and 100 mg twice daily). At the highest dose, HIV RNA levels dropped by 1.96 log10 copies/mL, a reduction comparable to potent oral antiretroviral combinations. The 100 mg dose achieved plasma concentrations that remained above the IC50 throughout the dosing interval.[2]
Cooper et al. (2004) reviewed enfuvirtide's clinical development from the first-in-human study through Phase III registration trials (TORO-1 and TORO-2). In these trials, adding enfuvirtide to an optimized background regimen produced significantly greater viral suppression than the background regimen alone in patients with extensive resistance to existing drug classes.[3] For the full enfuvirtide clinical story, see enfuvirtide (Fuzeon): the HIV peptide drug that blocks viral fusion.
Resistance and the HR1 Hotspot
Resistance to enfuvirtide develops through mutations in the HR1 region of gp41, specifically residues 36 through 45. Position 38 is the primary hotspot: single amino acid substitutions at this position confer moderate to high-level resistance. Combinations of HR1 mutations can produce over 100-fold resistance.
The mechanism is straightforward: mutations alter the shape of the HR1 groove so that enfuvirtide no longer fits, while preserving enough groove structure for the native HR2 to complete 6HB formation. Pu et al. (2019) reviewed the broader landscape of protein- and peptide-based HIV entry inhibitors, noting that newer peptides targeting different regions of gp41 or using modified scaffolds can overcome enfuvirtide-resistant mutations.[7]
Next-Generation Fusion Inhibitor Peptides
Lipopeptides and Cholesterol Conjugates
One approach to improving peptide fusion inhibitors is conjugating them with lipid moieties that anchor the peptide to cell membranes. Cholesterol-conjugated HR2 peptides show dramatically increased potency (up to 100-fold) because the lipid anchor concentrates the peptide at the membrane surface where fusion occurs, increasing the local concentration at the site of action.
Nanobody-Peptide Conjugates
Saha et al. (2026) described a semisynthetic strategy combining nanobodies (small antibody fragments) with fusion inhibitor peptides. Using site-selective enzymatic ligation and click chemistry, they created nanobody-fusion inhibitor conjugates that combined the specificity of antibody targeting with the mechanistic potency of HR2 peptides. The conjugates showed remarkably potent anti-HIV activity with broad neutralization breadth, representing a next-generation approach to fusion inhibition.[4]
Stapled Peptides
Stocks et al. (2021) characterized hydrocarbon-stapled enfuvirtide variants, where a chemical staple locks the peptide into its alpha-helical bioactive conformation. Stapling can increase protease resistance, improve membrane penetration, and enhance binding affinity to the HR1 target. Ion mobility mass spectrometry confirmed that stapled enfuvirtide maintains the correct helical structure while gaining stability benefits.[8]
Vaccine Applications
Erdmann et al. (2025) took the fusion inhibitor concept in a different direction: using gp41 MPER (membrane-proximal external region) peptides as vaccine immunogens. In the HVTN133 Phase I clinical trial, a peptide-liposome vaccine based on the gp41 MPER region elicited neutralizing antibodies targeting the same fusion machinery that enfuvirtide blocks pharmacologically. This represents a convergence of therapeutic and preventive peptide strategies targeting the same viral protein.[9]
Beyond HIV: The Universal Fusion Inhibitor Principle
The six-helix bundle mechanism is not unique to HIV. Many enveloped viruses use class I fusion proteins with similar HR1/HR2 architectures: SARS-CoV-2, RSV, Ebola, influenza, Nipah, and parainfluenza viruses all share this structural feature. Gonepudi et al. (2025) reviewed structure-guided design of peptide inhibitors across these class I fusion proteins, noting that the same HR2-mimetic strategy that works against gp41 can be adapted to target the HR1 domains of other viral fusion proteins.[5]
This has already produced clinical candidates. The EK1 peptide, designed to target the HR1 domain of SARS-CoV-2 spike protein, uses the same competitive inhibition mechanism as enfuvirtide but against a different virus. Lipopeptide derivatives of EK1 (such as EK1C4) show picomolar potency against SARS-CoV-2 by combining HR2-mimetic binding with membrane anchoring. The structure-guided approach described by Gonepudi et al. enables rational design of HR2-mimetic peptides against any class I fusion protein once the HR1 crystal structure is solved, turning a 30-year-old HIV discovery into a pan-viral therapeutic platform. For more on antiviral peptide approaches, see cyclotides and HIV: plant peptides with antiviral properties.
Limitations
Enfuvirtide's clinical use has declined since its approval in 2003, not because the mechanism failed but because newer oral antiretroviral drugs are more convenient. Twice-daily subcutaneous injections cause injection site reactions in the majority of patients, and the manufacturing cost is high (the peptide requires complex solid-phase synthesis). These practical barriers, not efficacy limitations, drove the shift away from enfuvirtide as a routine therapy.
The transient window for peptide binding between fusion peptide insertion and 6HB formation is brief. The kinetics of 6HB formation are fast, meaning the peptide must be present at sufficient concentration at the exact time and place where fusion occurs. This explains why high systemic concentrations are needed for clinical efficacy.
The resistance barrier, while lower than ideal (single mutations at HR1 position 38 can confer significant resistance), is partially mitigated by the fact that HR1 mutations often reduce viral fitness. Resistant viruses must maintain enough HR1 groove structure for native HR2 binding while simultaneously evading the therapeutic peptide, and this trade-off limits the degree of resistance that can accumulate without cost to the virus.
No next-generation peptide fusion inhibitor has been approved since enfuvirtide in 2003, despite promising preclinical candidates. The clinical development pipeline has been slower than the scientific advances suggest it should be, partly because the success of oral integrase inhibitors and next-generation protease inhibitors has reduced the unmet need that originally drove enfuvirtide's development. Whether the newer peptide approaches (nanobody conjugates, stapled peptides, lipopeptides) will reach clinical approval depends as much on the evolving HIV treatment landscape as on their inherent potency.
The Bottom Line
Peptide fusion inhibitors block HIV entry by mimicking the HR2 region of gp41 and binding competitively to the HR1 trimer groove, preventing six-helix bundle formation. Enfuvirtide (T-20) demonstrated this principle clinically with potent viral load reductions at concentrations below 2 ng/mL. The mechanism is effective against multidrug-resistant HIV because it targets the entry step rather than intracellular enzymes. Next-generation approaches include lipopeptide conjugates, nanobody-peptide fusions with 100-fold improved potency, and stapled peptides with enhanced stability. The same mechanistic principle applies to other enveloped viruses with class I fusion proteins.